retatrutide clinical trial south korea retatrutide korea approval Retatrutide Dosing: Early Clinical Trial Insights on How It Might Work-150cent S. Korean companies join global

That is a five-day gap (well above 48 hours)

GLP-1 medications should be stopped if pancreatitis develops, and should likely be avoided in anyone with pre-existing gastroparesis

They are injectable medications prescribed to help people with obesity or type 2 diabetes

According to KFF analysis of Centers for Medicare & Medicaid Services 2018-2022 Medicare Part D spending by drug increased from $57 Million to $5.7 Billion.[2] The June 13, 2024 article in Fierce Healthcare[3] on GLP-1 drugs noted that Blue Cross Blue Shield of Michigan will no longer cover these drugs starting in January 2025, and will be changing the prior authorization criteria starting in August 2024, for those members that are in large group fully insured commercial plans